Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.5696
- Book/Share 9.1268
- PB 6.1292
- Debt/Equity 2.7512
- CurrentRatio 1.2663
- ROIC 0.1414
- MktCap 113584840141.0
- FreeCF/Share 7.5085
- PFCF 7.4229
- PE 18.829
- Debt/Assets 0.5268
- DivYield 0.0446
- ROE 0.3465
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BMY | UBS | Neutral | Buy | -- | $65 | Jan. 7, 2026 |
| Upgrade | BMY | BofA Securities | Neutral | Buy | -- | $61 | Dec. 15, 2025 |
| Upgrade | BMY | Guggenheim | Neutral | Buy | -- | $62 | Dec. 12, 2025 |
| Initiation | BMY | Scotiabank | -- | Sector Perform | -- | $45 | Nov. 13, 2025 |
| Downgrade | BMY | Daiwa Securities | Outperform | Neutral | -- | $42 | Aug. 5, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
Read More
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Read More
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Published: December 24, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY and overtaking legacy drugs, supporting a bullish outlook. Despite modest 3% total revenue growth, BMY maintains robust margins, strong cash flow, and a 4.65% dividend yield, enhancing its defensive appeal.
Read More
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
Read More
Jenny Harrington's top dividend plays for 2026
Published: December 23, 2025 by: CNBC Television
Sentiment: Neutral
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to share her top dividend plays for 2026.
Read More
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of exclusivity risks, BMY's growth portfolio delivered 18% growth in Q3 and now exceeds 50% of business mix. Robust free cash flow margins (>30%) and a 4.7% yield provide BMY investors with attractive compensation while awaiting pipeline catalysts.
Read More
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Read More
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
Published: December 15, 2025 by: Benzinga
Sentiment: Positive
BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE: BMY), citing near-term catalysts.
Read More
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
Read More
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Read More
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
Published: December 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
Read More
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
Read More
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Read More
A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.
Published: December 03, 2025 by: Market Watch
Sentiment: Positive
Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.
Read More
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
Published: December 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
Published: December 03, 2025 by: Barrons
Sentiment: Positive
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100